McDermott Will & Schulte advised Fidia Farmaceutici S.p.A. on its acquisition of Altacor Ltd, a UK based ophthalmic products company. The transaction marks a significant strategic step for Fidia as it enters the UK ophthalmology market directly, enhancing its presence in one of the group's core therapeutic areas.
Through the acquisition, Fidia expands its portfolio with Altacor's established brands, including the Clinitas product lines dedicated to dry eye treatment. The deal also positions Fidia to introduce its own next generation hyaluronic acid–based solutions (FHA 1.0) into the UK market, covering artificial tears, diagnostic dyes, ophthalmic food supplements and surgical aids for cataract procedures and corneal cross linking.
McDermott advised Fidia with a multidisciplinary, cross border team spanning corporate, M&A, regulatory, IP and employment matters. The transaction team was coordinated by partner Alfonso Annibale de Marco, together with partners Ettore Scandale (Milan) and Jason Zemmel, Sharon Lamb and Christopher Marshall (London).